Clinical 10:04 ET · Sep 10, 2026 ● Checked against the source IMNN IMUNON Signs CRADA With National Cancer Institute for IMNN-001 The NCI's Cancer Therapy Evaluation Program will sponsor and fund new trials of IMUNON's DNA-based IL-12 immunotherapy in additional solid tumors. Andre·2 min read ID: IMNN-2026-09-10-1004 TickersIMNN Clinical DeskClinical PublishedSep 10, 2026 · 10:04 ET AccessPro story MORE FROM THE DESK Sep 11 · 08:33 ETIMMUTEP Narrows Efti Strategy After TACTI-004 Failure, Blames ManufacturingSep 10 · 08:45 ETEYEPOINT Details LUGANO Miss, Says Nine Patients Drove Failed EndpointSep 9 · 06:13 ETBRIDGEBIO Says Oral Infigratinib Cut Ear Infections, Stabilized Sleep ApneaSep 8 · 13:53 ETVERU Pushes Oral Sabizabulin Into Phase 2 for Daraxonrasib-Resistant Pancreatic Cancer
